Pharmaxis Ltd is an Australian pharmaceutical research company developing drugs for inflammatory and fibrotic diseases, with a focus on myelofibrosis.
The company has a highly productive drug discovery engine built on its expertise in the area of amine oxidase inhibitors, with drug candidates in clinical trials. Pharmaxis has also developed two respiratory products which are approved and supplied in global markets, generating ongoing revenue. The Pharmaxis manufacturing and research facilities are in Sydney.
The Pharmaxis drug development pipeline includes its drug PXS-5505 for the bone marrow cancer myelofibrosis which is also being investigated as a potential treatment for other cancers such as liver and pancreatic cancer. Other drug candidates are targeting fibrotic diseases such as kidney fibrosis, NASH, pulmonary fibrosis and cardiac fibrosis; fibrotic scarring from burns and other trauma; and inflammatory diseases.
Pharmaxis has used its amine oxidase inhibitor expertise to develop a dual amine oxidase inhibitor which is designed to exert a double effect - to protect muscle and to reduce inflammation and organ fibrosis in Duchenne Muscular Dystrophy (DMD), a devastating genetic disorder affecting thousands of Australians. DMD is characterised by muscular degeneration, with dramatic debilitating effects on mobility and daily functioning from a young age, and much reduced life expectancy. For patients this drug candidate could result in better daily functioning, improved quality of life and longer life expectancy.
The project will progress PXS-4699 to clinical trials in DMD patients and will involve close interaction with TREAT-NMD, an international network of neuromuscular disorder experts and patient associations.
BTB Round: Two
State: New South Wales
- MTPConnect Grant: $505,390
- Industry Contribution: $970,504
Duration: September 2020 – April 2022 (Terminated)
Contact: Dieter Hamprecht